Pankreaskarzinom

Pankreaskarzinom, commonly known as pancreatic cancer, is a malignant neoplasm originating in the tissues of the pancreas. It is characterized by its often late diagnosis and aggressive clinical course. The pancreas, an organ located in the abdominal cavity, plays a vital role in digestion and blood sugar regulation, with the most common types of pancreatic tumors arising from its exocrine gland cells.

The majority of pancreatic cancers are adenocarcinomas, which typically develop in the head of the pancreas, leading to early symptoms such as jaundice, weight loss, and abdominal pain. Less frequently, tumors can arise from the endocrine cells of the pancreas, known as neuroendocrine tumors, which tend to have a different prognosis and treatment approach.

Risk factors for developing pankreaskarzinom include smoking, chronic pancreatitis, diabetes mellitus, obesity, and a family history of pancreatic cancer. Genetic mutations, such as in the KRAS, CDKN2A, and TP53 genes, also play a role in the pathogenesis.

Diagnosis is often challenging due to the nonspecific initial symptoms. Imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound facilitate detection. Laboratory tests, including elevated levels of tumor markers like CA 19-9, can support diagnosis but are not definitive.

Treatment options depend on the stage of the disease at diagnosis. Surgical resection remains the only potential curative approach, primarily for localized tumors. However, since most cases are diagnosed at an advanced stage, chemotherapy and radiation therapy are commonly employed to improve quality of life and extend survival.

The prognosis of pankreaskarzinom is generally poor, with a five-year survival rate remaining low, highlighting the importance of early detection and ongoing research into more effective therapies.